サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1361767

細胞・遺伝子治療臨床試験の世界市場レポート

Global Cell And Gene Therapy Clinical Trials Market Report
出版日: | 発行: Value Market Research | ページ情報: 英文 127 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
細胞・遺伝子治療臨床試験の世界市場レポート
出版日: 2023年10月01日
発行: Value Market Research
ページ情報: 英文 127 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞・遺伝子治療臨床試験市場の世界需要は、2023年～2030年の調査期間中にCAGR20.72%で成長し、2022年の97億2,000万米ドルから2030年までに529億3,000万米ドルの市場規模に達すると推定されます。

細胞・遺伝子治療臨床試験は、バイオ医薬品における最も革新的なイノベーションの一つとして急速に台頭してきました。細胞・遺伝子治療は、神経学や眼科治療など、当初の腫瘍学を超える治療領域で試験されています。細胞・遺伝子治療臨床試験は、ライフサイエンス業界における革新の新しい波を提示しています。

市場力学：

細胞・遺伝子治療パイプラインの増加が市場成長率を押し上げる根本原因です。また、資金調達の増加、研究開発への投資、製品上市の成功が市場成長を後押ししています。さらに、細胞・遺伝子治療臨床試験市場は、過去数年間で著しい成長を遂げており、製薬会社は患者のために効果的で利用しやすい治療法を開発するために提携しています。さらに、細胞・遺伝子治療の臨床研究は昨年と比較して大幅に増加しています。これは、がんや希少疾患の治療の可能性があることから、研究者の関心が遺伝子治療に移っているためです。このシフトは市場成長を促進すると予想されます。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、細胞・遺伝子治療臨床試験の世界市場における各セグメントを包括的に評価することもできます。細胞・遺伝子治療臨床試験産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析：

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける細胞・遺伝子治療臨床試験市場の現在および将来の需要を強調する地域展望をカバーします。さらに、本レポートでは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 細胞・遺伝子治療臨床試験：産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 COVID-19発生の影響分析

第6章 世界の細胞・遺伝子治療臨床試験市場分析：フェーズ別

  • 概要：フェーズ別
  • 実績データと予測データ
  • 分析：フェーズ別
  • フェーズi
  • フェーズII
  • フェーズIII
  • フェーズIV

第7章 世界の細胞・遺伝子治療臨床試験市場分析：適応症別

  • 概要：適応症別
  • 実績データと予測データ
  • 分析：適応症別
  • 腫瘍学
  • 循環器
  • 中枢神経系
  • 筋骨格系
  • 感染症
  • 皮膚科学
  • 内分泌、代謝、遺伝学
  • 免疫・炎症
  • 眼科
  • 血液学
  • 消化器病学
  • その他

第8章 細胞・遺伝子治療臨床試験の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域の売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第9章 細胞・遺伝子治療臨床試験企業の競合情勢

  • 細胞・遺伝子治療臨床試験市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • IQVIA
  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International Inc.
  • PAREXEL International Corp.
  • Syneos Health
  • Medpace
  • Holdings Inc.
  • PPD Inc.
  • Novotech
  • Veristat LLC
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Phase (USD MN)
  • Phase I Market Sales by Geography (USD MN)
  • Phase II Market Sales by Geography (USD MN)
  • Phase III Market Sales by Geography (USD MN)
  • Phase IV Market Sales by Geography (USD MN)
  • Analysis Market by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Cardiology Market Sales by Geography (USD MN)
  • CNS Market Sales by Geography (USD MN)
  • Musculoskeletal Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Dermatology Market Sales by Geography (USD MN)
  • Endocrine, Metabolic, Genetic Market Sales by Geography (USD MN)
  • Immunology & Inflammation Market Sales by Geography (USD MN)
  • Ophthalmology Market Sales by Geography (USD MN)
  • Hematology Market Sales by Geography (USD MN)
  • Gastroenterology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Cell And Gene Therapy Clinical Trials Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Cell And Gene Therapy Clinical Trials Report
  • Market Research Process
  • Market Research Methodology
  • Global Cell And Gene Therapy Clinical Trials Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Phase
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Phase (USD MN)
  • Phase I Market Sales by Geography (USD MN)
  • Phase II Market Sales by Geography (USD MN)
  • Phase III Market Sales by Geography (USD MN)
  • Phase IV Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Cardiology Market Sales by Geography (USD MN)
  • CNS Market Sales by Geography (USD MN)
  • Musculoskeletal Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Dermatology Market Sales by Geography (USD MN)
  • Endocrine, Metabolic, Genetic Market Sales by Geography (USD MN)
  • Immunology & Inflammation Market Sales by Geography (USD MN)
  • Ophthalmology Market Sales by Geography (USD MN)
  • Hematology Market Sales by Geography (USD MN)
  • Gastroenterology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11218697

The global demand for Cell And Gene Therapy Clinical Trials Market is presumed to reach the market size of nearly USD 52.93 BN by 2030 from USD 9.72 BN in 2022 with a CAGR of 20.72% under the study period 2023 - 2030.

Cell and gene therapies clinical trials have quickly emerged as one of the most transformative innovations in biopharmaceuticals. CGTs are tested in therapeutic areas beyond their initial oncology focus, including neurology and ophthalmology treatment. Cell and gene therapy clinical trials present a new wave of innovation in the life sciences industry.

MARKET DYNAMICS:

The rise in the CGT pipeline is the root cause fuelling the market growth rate. Also, increasing funding, investments in research and development, and successful product launches are boosting the market growth. Moreover, the market of cell and gene therapy clinical trials has witnessed significant growth over the past few years, with pharma firms partnering to create effective and accessible therapies for patients. Furthermore, cell and gene therapy clinical studies increased significantly compared to last year, as researchers are now shifting their focus to gene therapy because of its potential to treat cancer or rare diseases. This shift is expected to fuel the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell and gene therapy clinical trials. The growth and trends of cell and gene therapy clinical trials industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cell and gene therapy clinical trials market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication

  • Oncology
  • Cardiology
  • CNS
  • Musculoskeletal
  • Infectious Diseases
  • Dermatology
  • Endocrine, Metabolic, Genetic
  • Immunology & Inflammation
  • Ophthalmology
  • Hematology
  • Gastroenterology
  • Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cell And Gene Therapy Clinical Trials market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cell and gene therapy clinical trials market include IQVIA, ICON Plc, Laboratory Corporation of America Holdings, Charles River Laboratories International, Inc., PAREXEL International Corp., Syneos Health, Medpace, Holdings, Inc., PPD Inc., Novotech, Veristat LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CELL AND GENE THERAPY CLINICAL TRIALS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Phase
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET ANALYSIS BY PHASE

  • 6.1 Overview by Phase
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Phase
  • 6.4 Phase I Historic and Forecast Sales by Regions
  • 6.5 Phase II Historic and Forecast Sales by Regions
  • 6.6 Phase III Historic and Forecast Sales by Regions
  • 6.7 Phase IV Historic and Forecast Sales by Regions

7 . GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 Oncology Historic and Forecast Sales by Regions
  • 7.5 Cardiology Historic and Forecast Sales by Regions
  • 7.6 CNS Historic and Forecast Sales by Regions
  • 7.7 Musculoskeletal Historic and Forecast Sales by Regions
  • 7.8 Infectious Diseases Historic and Forecast Sales by Regions
  • 7.9 Dermatology Historic and Forecast Sales by Regions
  • 7.10. Endocrine, Metabolic, Genetic Historic and Forecast Sales by Regions
  • 7.11 Immunology & Inflammation Historic and Forecast Sales by Regions
  • 7.12 Ophthalmology Historic and Forecast Sales by Regions
  • 7.13 Hematology Historic and Forecast Sales by Regions
  • 7.14 Gastroenterology Historic and Forecast Sales by Regions
  • 7.15 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE CELL AND GENE THERAPY CLINICAL TRIALS COMPANIES

  • 9.1. Cell And Gene Therapy Clinical Trials Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF CELL AND GENE THERAPY CLINICAL TRIALS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. IQVIA
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. ICON Plc
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Laboratory Corporation of America Holdings
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Charles River Laboratories International Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. PAREXEL International Corp.
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Syneos Health
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Medpace
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Holdings Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. PPD Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Novotech
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Veristat LLC
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies